Articles On Opthea (ASX:OPT)
Title | Source | Codes | Date |
---|---|---|---|
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | OPT | 2 weeks ago |
2 cheap ASX shares that offer at least 9% dividend yields
Cheap ASX shares are capable of paying very high dividend yields because of their cheap valuation. Assuming a dividend cut isn't coming, a big potential yield can be very appealing because of how much it can contribute to total sharehold... |
Motley Fool | OPT | 2 weeks ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | OPT | 3 weeks ago |
What are brokers saying about A2 Milk shares?
A2 Milk Company Ltd (ASX: A2M) shares are on form and rising nicely on Tuesday. At the time of writing, the infant formula company's shares are up almost 2% to $5.86. Why are A2 Milk shares rising? Investors may have been buying the company... |
Motley Fool | OPT | 3 weeks ago |
Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling today
Much to the relief of Aussie investors, the S&P/ASX 200 Index (ASX: XJO) is having a much better session on Thursday. In afternoon trade, the benchmark index is up 0.5% to 7,819.2 points. Four ASX shares that have failed to follow the... |
Motley Fool | OPT | 1 month ago |
Opthea appoints Sujal Shah to its board of directors
“It’s a privilege to join the Board of Opthea at such a transformative time,” said Sujal Shah. “I look forward to partnering with the executive leadership team and the Board as we continue to drive sozinibercept forward, with the go... |
BiotechDispatch | OPT | 1 month ago |
End in sight as Opthea looks to be key player in US$10 billion wet AMD market
Opthea look to transform standard of care treatment for wet AMD to improve vision outcomes Two Phase 3 trials are underway investigating lead drug OPT-302 with results from both forecast mid 2025 Opthea looking to be first drug statistical... |
Stockhead | OPT | 2 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | OPT | 2 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | OPT | 2 months ago |
ASX Health Stocks: Clarity’s imaging agent can identify prostate cancer lesions at double the rate
Clarity says initial data from Phase 1/2 trial is positive Opthea completes enrolment of all patients in the COAST Phase 3 trial ProMedicus locks in record half Clarity’s Phase 1/2 trial shows positive initial results Clarity Pharmaceut... |
Stockhead | OPT | 3 months ago |
Opthea completes enrolment in first pivotal trial with sozinibercept
Opthea (ASX:OPT) has announced that it has completed the enrolment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept in combination with aflibercept. |
BiotechDispatch | OPT | 3 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | OPT | 6 months ago |
Opthea announces leadership transition with the appointment of US-based executives
Opthea (ASX:OPT) has announced that CEO Dr Megan Baldwin will transition to founder and chief innovation officer, appointing US-based executives Dr Frederic Guerard as CEO and Peter Lang as chief financial officer. |
BiotechDispatch | OPT | 6 months ago |
Closing Bell: ASX ends flat, but it’s not a good flat. More an Oxford Dictionary ‘to lack vigour; dull and lifeless’ flat
Benchmark ASX index closes short by -0.04% Materials sector tries but cannot offset everyone else Small caps led by HAL, DTC The ASX200 Index has closed slightly lower after jumping early (+0.3%) out the gates on Wednesday morning. The... |
Stockhead | OPT | 6 months ago |
In Case You Missed It – BC Extra Upgrades & Downgrades – 20-10-23
Broker Rating Changes (PostThursday Last Week) Upgrade AMA GROUP LIMITED ((AMA)) Upgrade to Buy from Speculative Buy by Canaccord Genuity.B/H/S: 0/0/0 Having recently completed a $55m capital raise,AMA Group is set to deploy $35mto repay se... |
FNArena | OPT | 6 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | OPT | 6 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | OPT | 7 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | OPT | 8 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | OPT | 8 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | OPT | 8 months ago |
Top 10 at 11: Sarytogan Graphite up 51pc after Central Kazakhstan update
Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | OPT | 8 months ago |
Closing Bell: ASX200 makes it a hat-trick after Tech Sector triumph
ASX 200 benchmark rises almost 0.6% Tech Sector recovers Wednesday’s losses, after Nasdaq positivity Miners lead small cap gains, ERW, RDN, AZS winning at home in Andover South The Australian share market was up and about early on Thur... |
Stockhead | OPT | 8 months ago |
Biotech Opthea eyes $80m raise to back retinal disease therapy trials
Melbourne-headquartered biotech company Opthea (ASX: OPT) has kicked off an $80 million capital raise to support clinical development of its drug candidate aimed at treating wet AMD (age-related macular degeneration), the most common cause... |
businessnewsaustralia.com | OPT | 8 months ago |
Carlyle goes all in on biotech Opthea; MST launches $80m capital raise
The private equity giant has signalled its intention to take up an option to invest another $80 million in the clinical-stage biotech |
AFR | OPT | 8 months ago |
Opthea announces placement and fully underwritten entitlement offer to raise $80m
Clinical-stage biopharmaceutical company Opthea (ASX:OPT) has announced that it is seeking to raise $80 million through a $10 million private placement and a $70 million entitlement offer. |
BiotechDispatch | OPT | 8 months ago |
Move over Neuren – Bioshares reckons these ASX health stocks could pop with upcoming key catalysts
Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing... |
Stockhead | OPT | 8 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | OPT | 8 months ago |
MoneyTalks: Brokers say Rumble could surge 2x on zinc demand; Opthea 4x if clinical trials succeed
Rumble Resources’s share price could double on zinc demand Opthea could rise more than 4x after Phase 3 completions Development Global has a portfolio of future facing metals Wilsons says Rumble could double on zinc demand Wilsons Asset... |
Stockhead | OPT | 9 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | OPT | 9 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | OPT | 10 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | OPT | 11 months ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | OPT | 1 year ago |
Imugene (ASX:IMU) doses first patients in combination study of VAXINIA MAST trial
Highlights Imugene has advanced its ongoing Phase 1 MAST study with the first patients receiving dosing in the intratumoral (IT) and intravenous (IV) cohorts of CF33-hNIS in combination with Pembrolizumab. The study is focused on measu... |
Kalkine Media | OPT | 1 year ago |
Market Highlights: Defiant Wall Street, Man U for sale, and 5 ASX small caps to watch today
ASX 200 to rise on Tuesday ahead of the US CPI report Talk of extraterrestrial in US skies Manchester United reportedly for sale The ASX 200 is poised to rise on Tuesday, tracking the rally in New York. At 8am AEDT, the ASX 200 Feb futu... |
Stockhead | OPT | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | OPT | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | OPT | 1 year ago |
Investing in ASX biotech ft. Dr Megan Baldwin & Jeremy Curnock Cook
Jeremy Curnock Cook is the Managing Director and founder of BioScience Managers, a funds management business specialising in biotechnology investments in Australia and globally. He is also a director of Avita Medical Inc (ASX: AVH). Jeremy... |
Rask Media | OPT | 1 year ago |
The A to Z of Dr Boreham’s Crucible in 2022
The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,... |
Stockhead | OPT | 1 year ago |
Eye on Lithium: Biden inks $2.5bn loan for construction of three US battery plants
Lightning Minerals identifies multiple pegmatite intrusion outcrops at Dundas project Galan moves to 100pc ownership of the Green Bushes South Lithium Project Critical Resources’ recent assay results at Mavis Lake extends the current strik... |
Stockhead | OPT | 1 year ago |
Long-short funds – why you don’t necessarily have to lose money in a bear market
A decline in the stock market doesn’t mean you necessarily have to lose money Retail investors are not allowed to open a short-selling broker account in Australia But there is a handful of long-short and short-only funds available on the A... |
Stockhead | OPT | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | OPT | 1 year ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | OPT | 1 year ago |
After falling 16% in 2 weeks, is the Bendigo Bank share price too cheap to miss?
The Bendigo and Adelaide Bank Ltd (ASX: BEN) share price has suffered in August. Itâs down by 16% in just two weeks. For a business as large as Bendigo Bank, thatâs a significant fall in a short amount of time when the S&P/ASX 200... |
Motley Fool | OPT | 1 year ago |
Is the Beach Energy share price a buy following its post-reporting sell-off?
The Beach Energy Ltd (ASX: BPT) share price plummeted 11% on Monday following the release of the companyâs financial year 2022 earnings. The stock closed yesterdayâs session at $1.645. Unfortunately, brokers shared in the marketâs di... |
Motley Fool | OPT | 1 year ago |
Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials
Biopharmaceutical company Opthea (OPT) receives binding commitments for a US$90 million (A$127 million) two-tranche placement to institutional investors at $1.15 per share The clinical-stage healthcare stock has also secured up to US$170 m... |
themarketherald.com.au | OPT | 1 year ago |
Why did the Opthea share price dive 9% on Monday?
The Opthea Limited (ASX: OPT) share price closed 9.35% lower on Monday after the company announced details of a new share issue. Shares of the biopharmaceutical company finished the day at $1.26 each after opening at $1.39 this morning. Th... |
Motley Fool | OPT | 1 year ago |
Here are the 3 most heavily traded ASX 200 shares on Monday
The S&P/ASX 200 Index (ASX: XJO) is off to the races so far this Monday in a flying start to the week. At the time of writing, the ASX 200 has added a healthy 0.52% to back above 7,060 points. So let’s delve deeper into these gains an... |
Motley Fool | OPT | 1 year ago |
Why Beach, Bendigo and Adelaide Bank, Opthea, and Paradigm shares are sinking
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 7,072.6 points. Four ASX shares that have failed to follow the market higher today ar... |
Motley Fool | OPT | 1 year ago |
An ASX CEO’s three most important jobs
What, exactly, is a CEOâs job? It seems like a simple question. Maybe you even have a simple answer for it. Yes, the buck stops at the big desk in the corner office. Thatâs true. So âeverythingâ might be a good answer. Or, if youâ... |
Motley Fool | OPT | 1 year ago |
Bluescope share price lifts 5% on record earnings
The Bluescope Steel Ltd (ASX: BSL) share price is higher on Monday after the company impressed investors with its FY22 results. Shares in the steel producer currently trade hands for $17.74 each, a 5.03% gain, after reaching a high of $18.... |
Motley Fool | OPT | 1 year ago |